Olamide Vincent
Psychiatric/Mental Health · Wilmington, DENPI 1013474238
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,369, more than ten times the $146 reported in 2021. Among psychiatric/mental health clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $100.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$587
- Axsome Therapeutics, Inc.$552
- Vanda Pharmaceuticals Inc.$524
- Neurocrine Biosciences, Inc.$496
- Teva Pharmaceuticals USA, Inc.$392
- plus $1K from 10 others
What the payments were for
- Food & beverage$4,906100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $1,016 |
| Alkermes, Inc. | 5 | $587 |
| Axsome Therapeutics, Inc. | 5 | $552 |
| Vanda Pharmaceuticals Inc. | 7 | $524 |
| Neurocrine Biosciences, Inc. | 4 | $496 |
| Teva Pharmaceuticals USA, Inc. | 4 | $392 |
| AbbVie | 3 | $344 |
| Otsuka America Pharmaceutical, Inc. | 2 | $250 |
| E.r. Squibb & Sons, L.L.C. | 2 | $207 |
| Johnson & Johnson | 1 | $150 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Amgen | 1 | $93 |
| AstraZeneca | 1 | $83 |
| Cequr Corporation | 1 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,870
- CAPLYTA$822
- Fanapt$484
- ARISTADA$479
- Auvelity$475
- INGREZZA$398
- Austedo XR$353
- VRAYLAR$250
- SPRAVATO$150
- REXULTI$125
- QELBREE$125
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- ARISTADA INITIO$120
- COBENFY$118
How this compares
$4,906 in reported general payments places this provider in the 90th percentile of 177 psychiatric/mental health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 48 | $12,180 |
| EliquisApixaban | 27 | $8,535 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $7,345 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $6,864 |
| JardianceEmpagliflozin | 13 | $4,343 |
| Divalproex Sodium | 73 | $3,966 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $3,920 |
| Bumetanide | 51 | $1,787 |
| Levothyroxine Sodium | 76 | $1,622 |
| Metoprolol Succinate | 59 | $1,600 |
| Mirtazapine | 49 | $1,452 |
| Scopolamine | 11 | $1,401 |
| Lisinopril | 58 | $1,329 |
| Trazodone Hcl | 56 | $1,200 |
| Metformin Hcl | 46 | $1,152 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Wilmington
- Ronald TyreeWilmington$59K
- Jenika MilesWilmington$8K
- Stephanie McKayWilmington$6K
- Jacqueline ArmstrongWilmington$6K
- Elizabeth SewardWilmington$6K
- Jennifer RogersWilmington$5K
- Edwin SokalskiWilmington$5K
- Lisa ToyWilmington$5K
- Earl RobinsonWilmington$4K
- Katrese ThomasWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.